Archives
AM 281 and GLT-1 After Traumatic Brain Injury
2026-10-13
A mouse study links CB1 signaling, astrocytic GLT-1 regulation, neuronal injury, and cognitive dysfunction after traumatic brain injury, while leaving important translational and pharmacological questions unresolved.
Phosbind Biotin LC: Identity and Evidence Scope
2026-10-12
Phosbind Biotin LC is documented by APExBIO as a biotinylated phosphate-binding reagent for conceptual use in phosphorylated protein detection on PVDF membranes. No matched research paper was available, so claims about performance, comparative sensitivity, specificity, or biological outcomes remain unverified.
Acifran: What the HCAR Structures Show
2026-10-12
A source-grounded overview of what the 2025 HCAR3 and HCAR2 structural study establishes about Acifran, what remains uncertain, and why receptor structures should not be treated as evidence of clinical benefit.
STING Activation and Evidence Gaps
2026-10-11
The supplied 2026 Immunity study provides structural and functional evidence that GNE-6468 and PI4P cooperate in STING activation. It does not establish that GNE-6468 is superior to other agonists, that it is represented in the L1023 catalog, or that the mechanism translates into clinical benefit.
LC–MS/MS Maps GS-441524 Prodrug Conversion
2026-10-10
A January 2026 Microchemical Journal study established an LC–MS/MS approach for distinguishing the novel GS-441524 prodrug NGP-1 from released GS-441524 across gastric, blood, microsomal, and rat pharmacokinetic models. The work supports a multistage conversion model, while its implications remain limited to preclinical disposition and do not establish human pharmacokinetics, intracellular activation, or clinical antiviral efficacy.
7-AAD and CD38 CAR-T: Five Key Questions
2026-10-09
A source-grounded overview of how 7-AAD reports membrane integrity, what it can and cannot show in CD38 CAR-T research, and how to interpret evidence from a recent structural study without extending in vitro findings to clinical conclusions.
Multianimal MRI for Pancreatic Tumor Monitoring
2026-10-09
Kempinska and colleagues describe a multianimal MRI workflow that enables high-resolution anatomical imaging of up to four pancreatic cancer model animals in a single acquisition session. The study’s proof-of-concept use with gemcitabine in the KPC model illustrates how more efficient longitudinal imaging could support tumor enrollment and treatment-response assessment without treating imaging measurements as a substitute for biological or clinical endpoints.
SCH772984: ERK1/2 Inhibition in Cancer Research
2026-10-08
A source-grounded overview of SCH772984 as an ERK1/2 inhibitor, covering MAPK/ERK pathway biology, reported cancer-model findings, the relevance of angiotensin II signaling in nasopharyngeal carcinoma, and the limits of extrapolating supplier data to disease-specific mechanisms or clinical use.
SGC-CBP30: CREBBP/EP300 Bromodomain Inhibitor
2026-10-08
SGC-CBP30 is a CREBBP/EP300 bromodomain inhibitor used to study transcriptional coactivator biology and epigenetics research. Product-level potency and cellular observations support its use as a research probe, while the lung adenocarcinoma study provides mechanistic context rather than direct validation of SGC-CBP30 in LUAD.
NAD+ and Energy Stress: Five Evidence Questions
2026-10-07
A source-grounded overview of NAD+ biology, the AMPK–ULK1 energy-stress study, evidence quality, interpretation boundaries, and the limits of supplementation claims.
Amine Chemistry Shapes Lung-Selective mRNA Delivery
2026-10-07
Panda and colleagues combined a 30-member cationic micelle library with machine-learning analysis to show that amine identity influences mRNA binding, cellular performance, viability, and tissue distribution. The study identifies a trade-off between carrier–mRNA binding strength and functional protein expression, while linking in vitro measurements with lung-selective in vivo delivery.
Pertussis Toxin: Mechanism and Evidence Boundaries
2026-10-06
Pertussis toxin is an AB5-type protein exotoxin whose best-established molecular effect is disruption of inhibitory G-protein signaling and intracellular cAMP regulation. It is useful for whooping cough research and immune signaling studies, but the available TREM2 uveitis evidence does not directly establish a pertussis toxin–TREM2 mechanism.
NAD+ and Autophagy Under Energy Stress
2026-10-05
A source-grounded overview of NAD+ biology, AMPK–ULK1 signaling, and what recent findings mean for interpreting autophagy during cellular energy stress.
THZ1 and CDK7: Five Evidence Questions
2026-10-05
A source-grounded guide to THZ1, CDK7 inhibition, and what a 2026 adipogenesis study does—and does not—show about transcriptional regulation, evidence quality, and research scope.
Copper–Hexetidine Synergy in Oral Streptococci
2026-10-04
Grytten, Scheie, and Giertsen reported strong in vitro antibacterial synergy between copper and hexetidine against Streptococcus sobrinus and Streptococcus sanguis. Their findings support combination-based investigation of oral antimicrobials, while the study’s narrow strain set and planktonic model limit direct conclusions about dental plaque, biofilms, or clinical gingivitis treatment.